Secukinumab’s antipsoriatic effects confirmed in U.S. patient population
Pediatric News ,
American patients with psoriatic arthritis (PsA) and psoriasis who received the interleukin-17A inhibitor secukinumab (Cosentyx…
American patients with psoriatic arthritis (PsA) and psoriasis who received the interleukin-17A inhibitor secukinumab (Cosentyx…
Results from the CHOICE study suggest that both a 150 mg and 300 mg dose of secukinumab improved symptoms of psoriatic…